Scarica l'app Stockscreener
2.05
1.49%
0.03
Precedente Chiudi:
$2.02
Aprire:
$2.02
Volume 24 ore:
124.83K
Relative Volume:
0.42
Capitalizzazione di mercato:
$215.69M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-5.4118
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-5.53%
1M Prestazione:
-13.14%
6M Prestazione:
-15.29%
1 anno Prestazione:
-8.07%
Intervallo 1D:
$2.00
$2.06
Intervallo di 1 settimana:
$1.80
$2.11
Portata 52W:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.05 | 212.79M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Will ProQR Therapeutics N.V. see short term momentum2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
ProQR Therapeutics N.V. stock outlook for YEARPortfolio Growth Summary & Long-Term Growth Stock Strategies - Newser
Is ProQR Therapeutics N.V. stock entering bullish territoryEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Statistical indicators supporting ProQR Therapeutics N.V.’s strengthWeekly Stock Recap & AI Driven Price Predictions - Newser
Published on: 2025-08-16 03:26:16 - Newser
Can ProQR Therapeutics N.V. rally from current levels2025 Winners & Losers & Fast Exit and Entry Strategy Plans - Newser
How to track smart money flows in ProQR Therapeutics N.V.Portfolio Update Summary & Stepwise Swing Trade Plans - Newser
Real time alert setup for ProQR Therapeutics N.V. performance2025 Price Momentum & Short-Term Trading Alerts - Newser
Will breakout in ProQR Therapeutics N.V. lead to full recoveryJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - Newser
Candlestick signals on ProQR Therapeutics N.V. stock todayWeekly Trade Report & Weekly Sector Rotation Insights - Newser
How institutional ownership impacts ProQR Therapeutics N.V. stockJuly 2025 EndofMonth & Safe Capital Growth Tips - Newser
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Nigeria
How to build a dashboard for ProQR Therapeutics N.V. stock2025 Macro Impact & Fast Entry Momentum Alerts - Newser
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital - MarketBeat
How high can ProQR Therapeutics N.V. stock goShare Buyback & Technical Entry and Exit Tips - Newser
Real time breakdown of ProQR Therapeutics N.V. stock performanceInsider Selling & Intraday High Probability Alerts - Newser
Can ProQR Therapeutics N.V. recover in the next quarter2025 Price Action Summary & Long-Term Growth Plans - Newser
How to forecast ProQR Therapeutics N.V. trends using time seriesMomentum Prediction Based on AI Backtesting - Newser
What to do if you’re stuck in ProQR Therapeutics N.V.Share Buyback & Real-Time Buy Signal Notifications - Newser
Is ProQR Therapeutics N.V. stock a growth or value playMarket Performance Recap & Consistent Profit Alerts - Newser
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchFree Confirmed Setup With Expert Accuracy - Newser
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
Using economic indicators to assess ProQR Therapeutics N.V. potentialFree Technical Entry Strategy for Beginners - Newser
Volume spikes in ProQR Therapeutics N.V. stock – what they meanSummary of Trade Cycles in 5-Year Range - Newser
ProQR's Strategic Advancements and Clinical Prospects Drive Buy Rating with $12 Price Target - AInvest
Live market analysis of ProQR Therapeutics N.V.Safe Momentum Strategy With Trend Analysis - Newser
Published on: 2025-08-10 23:41:36 - Newser
Using Ichimoku Cloud for ProQR Therapeutics N.V. technicalsFree Price Action Based Buy Opportunity List - Newser
Ranking ProQR Therapeutics N.V. among high performing stocks via toolsTechnical Safety Zone Pattern Recognition - Newser
ProQR Therapeutics (PRQR) to Release Earnings on Thursday - MarketBeat
Is ProQR Therapeutics N.V. in Accumulation Phase NowMarket Momentum Signal Generator Shows Trends - beatles.ru
ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):